Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | GeneticVariation | disease | BEFREE | We systematically searched Cochrane Library, PubMed, EMBASE, and Medline for randomized controlled trials (RCTs) comparing mTOR inhibitors to placebo in ADPKD patients up to August 2019. | 31578673 | 2019 | ||||
|
0.080 | GeneticVariation | disease | BEFREE | Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disease, and sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to significantly retard cyst expansion in animal models. | 20642692 | 2010 | ||||
|
0.080 | Biomarker | disease | BEFREE | In this review, we will discuss the mTOR pathway thoroughly, mainly focusing on current advances in understanding its role in ADPKD, especially the recent progress of mTOR inhibitors use in preclinical studies and clinical trials. | 29600752 | 2019 | ||||
|
0.080 | Biomarker | disease | BEFREE | Finally, no data currently support the preferential use of mammalian target of rapamycin inhibitors as immunosuppressive agents in transplant recipients with ADPKD. | 24935705 | 2014 | ||||
|
0.080 | Biomarker | disease | BEFREE | Available clinical data on mTOR inhibition in autosomal dominant polycystic kidney disease (ADPKD) is also briefly presented. | 31080770 | 2019 | ||||
|
0.080 | Biomarker | disease | BEFREE | The mammalian target of rapamycin (mTOR) cascade is one of the important pathways regulating cyst growth in ADPKD. | 28341273 | 2017 | ||||
|
0.080 | Biomarker | disease | BEFREE | We generated zebrafish mutants for pkd1 and noted cystic kidney and mTOR activation in pkd1a mutants, suggesting a conserved ADPKD model. | 28007903 | 2017 | ||||
|
0.080 | Biomarker | disease | BEFREE | Our findings suggest that multi-target PI3K/mTOR inhibition may represent a potential treatment for ADPKD. | 29615724 | 2018 |